Last reviewed · How we verify
Heparin Full Dose
At a glance
| Generic name | Heparin Full Dose |
|---|---|
| Sponsor | University Hospital, Bordeaux |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing (PHASE3)
- Bivalirudin With Prolonged Full Dose Infusion Versus Heparin Alone During Emergency PCI (NA)
- 'Thrombectomy in High-Risk Pulmonary Embolism - Device Versus Thrombolysis Netherlands': TORPEDO-NL (NA)
- Islet Allotransplantation in Type 1 Diabetes (PHASE1)
- Treatment of Pelvic Ring Fractures in the Elderly (NA)
- Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial (PHASE4)
- rCSP/AP10-602 [GLA-LSQ] Vaccine Trial (PHASE1)
- FREEDOM COVID-19 Anticoagulation Strategy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Heparin Full Dose CI brief — competitive landscape report
- Heparin Full Dose updates RSS · CI watch RSS
- University Hospital, Bordeaux portfolio CI